A recent headline announcing plans to transition commercial clients to a “rebate-free” model, passing previously negotiated drugs savings directly to members at the point of sale, marks yet another potential shift in the pharmacy landscape. The new proposed model underscores how quickly the industry is continuing to evolve and could reshape how plan sponsors, payers, employers, health plans, and health systems define value in 2026…
Beyond Diabetes and Obesity: The Expansion of GLP-1 Medications Glucagon-like peptide-1 (GLP-1) medications have revolutionized the treatment of diabetes and obesity, but their impact is rapidly broadening. Recent research and regulatory approvals reveal that GLP-1s may offer hope for a range of other health conditions, some of which might surprise you. Metabolic dysfunction-associated steatohepatitis (MASH)…
As the rebate landscape evolves, with biosimilars gaining traction and legislation reshaping pricing dynamics, staying ahead means having the right technology in place. The right tools can change everything, and Gateway Health Partner’s ProOptimizer is built to help you succeed. From complexity to clarity. ProOptimizer exists to help clients simplify their reporting by breaking down…
Discover how ProOptimizer can simplify complex rebate management with accurate, streamlined tools to help save time and optimize results. At Gateway Health Partners, our goal is to make the complex world of pharmacy rebate and formulary management easier to navigate. To do this our team of industry veterans and experts focus on building tools that…
By: Mike Strahan On July 16, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule that has the potential to significantly impact how 340B drugs are handled under Medicare Part D, and by extension, how pharmaceutical rebates are calculated. So, what does that mean? For context: beginning January 1, 2026, CMS is…